BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akhil MS, Kirushnan B, Martin M, Arumugam K, Ganesh Prasad NK, Ravichandran R. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Nephrology (Carlton) 2018;23:446-52. [PMID: 28339162 DOI: 10.1111/nep.13050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Fabrizi F, Cerutti R, Dixit V, Ridruejo E. Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología (English Edition) 2021;41:578-89. [DOI: 10.1016/j.nefroe.2021.11.011] [Reference Citation Analysis]
2 Li M, Chen J, Fang Z, Li Y, Lin Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. Virol J 2019;16:34. [PMID: 30871566 DOI: 10.1186/s12985-019-1140-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
3 Elmowafy AY, El Maghrabi HM, Eldahshan KF, Refaie AF, Elbasiony MA, Matter YE, Saleh HH, Shiha GE, Rostaing L, Bakr MA. Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality. Int Urol Nephrol 2019;51:1639-47. [PMID: 31363959 DOI: 10.1007/s11255-019-02246-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gohel K, Borasadia P. Sofosbuvir-Based HCV Treatment in Maintenance Hemodialysis Patients: A Single-Center Study. Transplant Proc 2020;52:1684-6. [PMID: 32507712 DOI: 10.1016/j.transproceed.2020.02.136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mehta R, Desai K, Kabrawala M, Nandwani S, Shah J, Desai N, Parekh V. Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis. Indian J Gastroenterol 2018;37:72-3. [PMID: 29430587 DOI: 10.1007/s12664-018-0833-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shehadeh F, Kalligeros M, Byrd K, Shemin D, Mylonakis E, Martin P, D'Agata EMC. Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Sci Rep 2020;10:14332. [PMID: 32868869 DOI: 10.1038/s41598-020-71205-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Premkumar M, Grover GS, Dhiman RK. Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs? J Clin Exp Hepatol 2017;7:253-61. [PMID: 28970713 DOI: 10.1016/j.jceh.2017.08.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Fabrizi F, Cerutti R, Dixit V, Ridruejo E. Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrologia 2021:S0211-6995(21)00091-6. [PMID: 34154846 DOI: 10.1016/j.nefro.2021.01.008] [Reference Citation Analysis]
9 Yang H, Hu X, Pu L, Ren S, Feng Y. Efficacy and safety of direct-acting antiviral-based treatment in hepatitis C virus infected patients with chronic renal function impairment: An updated systemic review and meta-analysis. Nephrology (Carlton) 2020;25:829-38. [PMID: 32108975 DOI: 10.1111/nep.13704] [Reference Citation Analysis]
10 Majd Jabbari S, Maajani K, Merat S, Poustchi H, Sepanlou SG. An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. PLoS One 2021;16:e0246594. [PMID: 33566846 DOI: 10.1371/journal.pone.0246594] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919 [PMID: 31413526 DOI: 10.3748/wjg.v25.i29.3897] [Reference Citation Analysis]